Abstract:Background: The 2022 outbreak of mpox (formerly known as monkeypox) led to the spread of monkeypox virus (MPXV) in over 110 countries, demanding effective disease management and surveillance. As current diagnostics rely largely on centralised laboratory testing, our objective was to develop a simple rapid point-of-care assay to detect MPXV in clinical samples using isothermal amplification coupled with CRISPR and CRISPR-associated protein (Cas) technology. Methods: In this proof-of-concept study, we developed a portable isothermal amplification CRISPR-Cas12a-based assay for the detection of MPXV. We designed a panel of 22 primer-guide RNA sets using pangenome and gene-agnostic approaches, and subsequently shortlisted the three sets producing the strongest signals for evaluation of analytical sensitivity and specificity using a fluorescence-based readout. The set displaying 100% specificity and the lowest limit of detection (LOD) was selected for further assay validation using both a fluorescence-based and lateral-flow readout. Assay specificity was confirmed using a panel of viral and bacterial pathogens. Finally, we did a blind concordance study on genomic DNA extracted from 185 clinical samples, comparing assay results with a gold-standard quantitative PCR (qPCR) assay. We identified the optimal time to detection and analysed the performance of the assay relative to qPCR using receiver operating characteristic (ROC) curves. We also assessed the compatibility with lateral-flow strips, both visually and computationally, where strips were interpreted blinded to the fluorescence results on the basis of the presence or absence of test bands. Findings: With an optimal run duration of approximately 45 min from isothermal amplification to CRISPR-assay readout, the MPXV recombinase polymerase amplification CRISPR-Cas12a-based assay with the selected primer-guide set had an LOD of 1 copy per μL and 100% specificity against tested viral pathogens. Blinded concordance testing of 185 clinical samples resulted in 100% sensitivity (95% CI 89·3-100) and 99·3% specificity (95% CI 95·7-100) using the fluorescence readout. For optimal time to detection by fluorescence readout, we estimated the areas under the ROC curve to be 0·98 at 2 min and 0·99 at 4 min. Lateral-flow strips had 100% sensitivity (89·3-100) and 98·6% specificity (94·7-100) with both visual and computational assessment. Overall, lateral-flow results were highly concordant with fluorescence-based readouts (179 of 185 tests, 96·8% concordant), with discrepancies associated with low viral load samples. Interpretation: Our assay for the diagnosis of mpox displayed good performance characteristics compared with qPCR. Although optimisation of the assay will be required before deployment, its usability and versatility present a potential solution to MPXV detection in low-resource and remote settings, as well as a means of community-based, on-site testing. Funding: Victorian Medical Research Accelerator Fund and the Australian Government Department of Health.

Detection of Mpox and other Orthopoxviruses using a Lateral Flow Device as a Point of Care diagnostic.

Rapid detection of monkeypox virus using a CRISPR-Cas12a mediated assay: a laboratory validation and evaluation study

Development of an extraction-free LAMP method for the generic detection of Orthopoxvirus and for the specific detection of Mpox virus

A field diagnostic method for rapid and sensitive detection of mpox virus

MpoxPlex: a high-throughput and versatile multiplexed immunoassay for assessing and discriminating between IgG responses to Mpox infection and vaccination

Analytical and clinical evaluation of a novel real-time PCR-based detection kit for Mpox virus

Diagnostic accuracy of three mpox lateral flow assays for antigen detection in the Democratic Republic of Congo and the United Kingdom

Rapid Detection of Monkeypox Virus by Multiple Cross Displacement Amplification Combined with Nanoparticle‐based Biosensor platform

Loop-mediated isothermal amplification coupled with nanoparticle-based lateral flow biosensor for monkeypox virus detection

A rapid and sensitive fluorescent chromatography with cloud system for MPXV point-of-care diagnosis

Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab samples

Evaluation of a multiplexed immunoassay for assessing long-term humoral immunity Orthopoxviruses

Development of a multiplex real-time PCR assay for the simultaneous detection of mpox virus and orthopoxvirus infections

A Label-free Optical Biosensor-Based Point-of-Care Test for the Rapid Detection of Monkeypox Virus

Evaluation of a commercial Multiplex Real-Time PCR Assay for orthopoxvirus and monkeypox virus detection, and simultaneous subclade Ib identification

Rapid detection of mpox virus using recombinase aided amplification assay

Evaluation of a low-cost, saliva-based PCR test for the detection of mpox virus

MASTR Pouch: Palm-size Lab for Point-of-care Detection of Mpox using Recombinase Polymerase Amplification and CRISPR Technology

Rapid and highly sensitive colorimetric LAMP assay and integrated device for visual detection of monkeypox virus

Development and Characterization of Recombinase-Based Isothermal Amplification Assays (RPA/RAA) for the Rapid Detection of Monkeypox Virus

CRISPR/Cas12a-mediated ultrasensitive and on-site monkeypox viral testing